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In this issue ofCancer Cell, Lu et al. describe unconventional molecular interactions in glioblastoma cells that
provide a mechanism for how anti-vascular endothelial growth factor therapy may promote mesenchymal
transition of glioblastoma cells and increase tumor invasion.Suppression of tumor angiogenesis using
neutralizing antibodies against vascular
endothelial growth factor (VEGF) initially
appeared to be a straightforward strategy
to starve the tumor and stop metastatic
spread. Indeed, the anti-VEGF neutral-
izing antibody bevacizumab has been
approved for the treatment of metastatic
colorectal cancer, non-squamous non-
small cell lung cancer, glioblastomamulti-
forme, and metastatic renal carcinoma.
Disappointingly, a significant fraction of
bevacizumab-treated patients carry
tumors that are insensitive to this therapy
or acquire resistance relatively quickly
(Bergers and Hanahan, 2008). The worri-
some findings that antiangiogenic therapy
may increase tumor invasiveness and
metastatic spread, described by the
Kerbel and Casanova groups (Ebos
et al., 2009; Pa`ez-Ribes et al., 2009),
have further complicated the application
of anti-VEGF treatment.
Data from the Bergers laboratory (Lu
et al., 2012), in this issue of Cancer Cell,
provide a possible explanation for the
increased invasiveness seen with anti-
VEGF therapy. Accordingly, blocking
VEGF leads to increased activity of the
hepatocyte growth factor (HGF) receptor
MET, and elimination of both MET and
VEGF expression from glioblastoma leads
to increased survival in experimental
models (Lu et al., 2012).
VEGF was originally described by Har-
vard Medical School researchers Donald
Senger and Harold Dvorak as vascular
permeability factor (VPF) and sub-
sequently identified as an endothelial
growth factor by Napoleone Ferrara
(Dvorak, 2006). Overwhelming evidence
in animal models and patients shows
that bevacizumab suppresses patholog-
ical tumor vascularization. VEGF binds
to two receptor tyrosine kinases, of which
VEGF receptor 2 (VEGFR2) is primarilyresponsible for VEGF’s effects on endo-
thelial cells in blood vessels (Koch et al.,
2011). Although initially perceived as en-
dothelial cell-specific, refined reagents
and analyses clearly show that VEGFR2
is expressed also in nonendothelial cells.
Indeed, Lu et al. (2012) show that VEGFR2
is expressed in glioblastoma cells. VEGF-
targeted therapy therefore may lead to
adverse and unexpected effects by sup-
pressing VEGFR2 on nonendothelial cells.
Glioblastoma multiforme is the most
aggressive form of brain cancer, with
a median survival of 18 months (Cham-
berlain, 2011). Treatment of recurrent
glioblastoma with bevacizumab prolongs
progression-free survival, particularly in
older patients. The effect of bevacizumab
is exerted atleast in part by reducing brain
edema, demonstrating that neutralization
of VEGF/VPF efficiently seals leaky tumor
vessels. That the reduced permeability
impairs contrast-enhanced magnetic res-
onance imaging, resulting in a false im-
pression of reduced tumor dimensions,
has confounded conclusions regarding
the clinical benefit of bevacizumab
therapy. In agreement with data from
animal models (Ebos et al., 2009; Pa`ez-
Ribes et al., 2009), there are indications
for increased invasiveness of the cancer
in bevacizumab-resistant glioblastoma,
resulting in therapy-inaccessible, infiltra-
tive growth along blood vessels (Cham-
berlain, 2011).
Interestingly, Lu et al. (2012) find that
VEGFR2 is engaged in a constitutive
complex with MET, which also includes
a cytoplasmic phosphotyrosine phospha-
tase, PTP1B. PTPs, including PTP1B,
serve dual roles in cancer and are impli-
cated as both tumor suppressors and
promoters of oncogenesis (Julien et al.,
2011). In the scenario described by Lu
et al. (2012), VEGFR2 directs the action
of PTP1B toward HGF-activated MET,Cancer Cleading to MET dephosphorylation and
thereby suppression of cell motility.
Blocking VEGF through bevacizumab
treatment unleashes HGF/MET activity
by disengaging the phosphatase from
the VEGFR2/MET complex. The fullblown
MET activity in its turn promotes invasive-
ness (Figure 1), involving induction of
a gene transcription program in the tumor,
reminiscent of epithelial-to mesenchymal
transition. Importantly, the Lu et al.
(2012) study shows increased MET phos-
phorylation and, therefore, activity in
gliomas from bevacizumab-treated
patients.
The study by Lu et al. (2012) raises
several critical questions regarding
growth factor signaling. For example,
does VEGFR2 signaling have cell-specific
traits? VEGFR2 stimulates a wide spec-
trum of signaling pathways in endothelial
cells resulting in survival, proliferation,
migration, and formation of lumenized
3D vessel structures (Koch et al., 2011).
This biology involves several of the most
well-known signaling pathways, such as
the RAS-RAF-ERK pathway and the
PI3K/AKT pathway, which operate down-
stream of most growth factor receptors in
most cell types. Surprisingly, VEGFR2
does not seem to contribute as a positive
regulator in glioma cells. And why does
VEGFR2 serve as a gate-keeper of MET
activity in glioblastoma cells but not, as
far as is known, in endothelial cells, which
also express MET?
Furthermore, the PTP1B-mediated
dephosphorylation is specific for MET
and does not affect VEGFR2, even though
the molecules exist in complex, implying
a level of specificity that is difficult to
comprehend in molecular terms. It does
not seem to involve the famous VEGF cor-
eceptor, neuropilin-1. Why, where, and
how do these unconventional molecular
complexes arise? Are they enriched inell 22, July 10, 2012 ª2012 Elsevier Inc. 1
Figure 1. VEGF Suppresses MET Phosphorylation and Signaling via PTP1B
In glioblastoma cells, MET and VEGFR2 exist in a complex that also includes PTP1B, which allows growth
of the tumor (left). Treatment with bevacizumab to neutralize VEGF reduces PTP1 activity and promotes
MET signaling, leading to increased invasion (middle). Combined treatment to neutralize HGF and
VEGF leads to efficient suppression of glioblastoma invasion (right). VEGFR2 (red) and MET (green) are
indicated as monomers or dimmers, with the kinase domain shown as a rectangle, either phosphorylated
(P) or not. The Pac-man symbol indicates PTP1B (orange). Intense colors indicate induction of enzymatic
activities of kinases and the phosphatase. VEGF and HGF are shown either bound to their cognate
receptors or as neutralized by specific antibodies against VEGF (middle) or HGF and VEGF (right). As
an alternative to HGF antibodies, MET kinase inhibitors may be used clinically. PM, plasma membrane.
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Previewsplasma membrane microdomains so
densely packed with signal transducers
that molecular interactions can occur
also between unrelated receptor tyrosine
kinases (Figure 1)? The interactions
seem specific; at least Lu et al. (2012)
could not detect any effects of PDGF
and EGF on MET activity.
The study by Lu et al. (2012) has several
novel implications with regard to optimi-
zation of treatment for glioblastoma multi-
forme and other forms of cancer. First,
combined treatment with agents blocking
HGF or MET in combination with bevaci-
zumab should have the important double
benefit of reducing edema and prevent-
ing invasiveness of the glioma cells. As
the clinical development of efficient
HRG and MET inhibitors is being actively2 Cancer Cell 22, July 10, 2012 ª2012 Elsevipursued (Gherardi et al., 2012), combined
treatment may be implemented very
soon. Second, although there appear to
be glioma-specific vascular aspects
such as transdifferentiation of glioma
stem cells to form vascular channels
(Chamberlain, 2011), it is likely that
VEGFR2 or other receptor tyrosine
kinases also present PTP1B to MET in
other types of malignancies. Indeed, Sen-
nino et al. (2012) recently demonstrated
that combined inhibition of MET and
VEGF signaling suppresses tumor inva-
sion and metastasis in neuroendocrine
tumors in mouse models. Finally, the
community is wise to expect further
hurdles on the road toward efficient anti-
angiogenic therapy. Still, the obstacles
we have encountered this far are, at leaster Inc.in hindsight, not very surprising, and are
consistent with what we know about
VEGF biology. High-quality basic re-
search on VEGF and its mechanisms of
action remains crucial for overcoming
these hurdles, as demonstrated by Berg-
ers and her colleagues.ACKNOWLEDGMENTS
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